U.S. markets open in 20 minutes
  • S&P Futures

    4,385.00
    -26.75 (-0.61%)
     
  • Dow Futures

    34,886.00
    -88.00 (-0.25%)
     
  • Nasdaq Futures

    14,873.00
    -164.75 (-1.10%)
     
  • Russell 2000 Futures

    2,228.00
    -9.50 (-0.42%)
     
  • Crude Oil

    73.56
    -0.06 (-0.08%)
     
  • Gold

    1,826.40
    -9.40 (-0.51%)
     
  • Silver

    25.52
    -0.26 (-1.02%)
     
  • EUR/USD

    1.1879
    -0.0017 (-0.14%)
     
  • 10-Yr Bond

    1.2510
    -0.0180 (-1.42%)
     
  • Vix

    18.89
    +0.58 (+3.17%)
     
  • GBP/USD

    1.3945
    -0.0013 (-0.09%)
     
  • USD/JPY

    109.7580
    +0.2970 (+0.27%)
     
  • BTC-USD

    38,767.81
    -1,018.57 (-2.56%)
     
  • CMC Crypto 200

    920.39
    -9.96 (-1.07%)
     
  • FTSE 100

    7,024.57
    -53.85 (-0.76%)
     
  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CCXI, ATER and SPCE

·3 min read

NEW YORK, NY / ACCESSWIRE / June 24, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

ChemoCentryx, Inc. (NASDAQ:CCXI)
Class Period: November 26, 2019 - May 6, 2021
Lead Plaintiff Deadline: July 6, 2021

The CCXI lawsuit alleges that ChemoCentryx, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in CCXI: http://www.kleinstocklaw.com/pslra-1/chemocentryx-inc-loss-submission-form?id=17148&from=1

Aterian, Inc. (NASDAQ:ATER)
Class Period: December 1, 2020 - May 3, 2021
Lead Plaintiff Deadline: July 12, 2021

The complaint alleges that throughout the class period Aterian, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's organic growth is plummeting; (ii) the Company's recent, self-lauded acquisitions were overpayments for flawed assets from questionable sources; (iii) Aterian's purported artificial intelligence software is a flawed product that lacks customer interest; (iv) Aterian uses rebate programs and paid or artificial reviews to pump up their product offerings; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ATER: https://www.kleinstocklaw.com/pslra-1/aterian-inc-loss-submission-form?id=17148&from=1

Virgin Galactic Holdings, Inc. (NYSE:SPCE)
Class Period: October 26, 2019 - April 30, 2021
Lead Plaintiff Deadline: July 27, 2021

During the class period, Virgin Galactic Holdings, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) for accounting purposes, Social Capital Hedosophia Holdings Corp.'s ("SCH") warrants were required to be treated as liabilities rather than equities; (ii) Virgin Galactic had deficient disclosure controls and procedures and internal control over financial reporting; (iii) as a result, the Company improperly accounted for SCH warrants that were outstanding at the time of the business combination; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in SPCE: https://www.kleinstocklaw.com/pslra-1/virgin-galactic-holdings-inc-loss-submission-form?id=17148&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/652956/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-CCXI-ATER-and-SPCE